Search our Database of Scientific Publications and Authors

I’m looking for a

    2481 results match your criteria Cutaneous B-Cell Lymphoma

    1 OF 50

    Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
    Cell Cycle 2017 Nov 20:1-29. Epub 2017 Nov 20.
    a Oncoceutics, Inc. , Philadelphia , PA.
    ONC201, founding member of the imipridone class of small molecules, is currently being evaluated in advancer cancer clinical trials. We explored single agent and combinatorial efficacy of ONC201 in preclinical models of hematological malignancies. ONC201 demonstrated (GI50 1-8 µM) dose- and time-dependent efficacy in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Burkitt's lymphoma, anaplastic large cell lymphoma (ALCL), cutaneous T-cell lymphoma (CTCL), Hodgkin's lymphoma (nodular sclerosis) and multiple myeloma (MM) cell lines including cells resistant to standard of care (dexamethasone in MM) and primary samples. Read More

    Mutations in Coagulation Factor VIII Are Associated with More Favorable Outcome in Patients with Cutaneous Melanoma.
    TH Open 2017 Jul;1(2):e113-e121
    Divisions of Laboratory Medicine, The University of Alabama at Birmingham, AL 35249.
    Coagulation factor VIII (FVIII), von Willebrand factor (VWF), and ADAMTS13 play an important role in regulation of normal hemostasis. However, little is known about their roles in patients with malignancy, particularly with cutaneous melanoma. Whole genome sequencing data are available for 25,719 cases in 126 cancer genomic studies for analysis. Read More

    A Slowly Developed Severe Cutaneous Adverse Reaction to Idelalisib.
    J Eur Acad Dermatol Venereol 2017 Nov 17. Epub 2017 Nov 17.
    PEDEGO Research Unit, University of Oulu, Department of Dermatology and Medical Research Center Oulu, Oulu University Hospital, Oulu, Finland.
    Intracellular signal mediator phosphatidylinositol-3-kinase (PIK3K) -δ, an isoform of PIK3K, is expressed in hematopoietic cells especially in lymphoid lineage 1. Idelalisib is a novel PIK3K-δ targeted kinase inhibitor which is approved for relapsed follicular B-cell non-Hodgkin lymphoma as a monotherapy and in combination with rituximab, an anti-CD20 antibody, for relapsed chronic lymphocytic leukemia (CLL) 2. Only one case describing the clinical features of severe cutaneous adverse reaction (SCAR) of idelalisib in detail has been previously published 3. Read More

    Diffuse Large B-Cell Lymphoma at the Site of a Herpes Zoster Scar.
    World J Oncol 2012 Aug 26;3(4):199-203. Epub 2012 Aug 26.
    Depts of Dermatology, MD Anderson Cancer Center and University of Texas Medical School at Houston, Houston, Texas; 6655 Travis Street, Suite 980 Houston, Texas 77030, USA.
    Herpes zoster, also known as shingles, occurs upon reactivation of a primary infection with varicella zoster virus (VZV). Risk factors for reactivation include stress, older age, and immunosuppression, all of which are associated with a decrease in host immunity. Common complications of herpes zoster include scarring and post-herpetic neuralgia (PHN). Read More

    Primary cutaneous B-cell lymphoma: narrative review of the literature.
    G Ital Dermatol Venereol 2017 Nov 16. Epub 2017 Nov 16.
    Dermatology Unit, IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
    Primary Cutaneous B-cell Lymphomas comprehend a group of lymphoproliferative disorders characterized by being monoclonal proliferations of B-cell primarily involving the skin. Despite being recognized as autonomous and distinct clinico-pathologic entities since the late 80s, their classification is still an ongoing matter of debate. At the moment, WHO classification recognizes three disorders: primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma and primary cutaneous diffuse large B-cell lymphoma, leg type. Read More

    PD-L1 and PD-L2 are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
    Am J Surg Pathol 2017 Nov 3. Epub 2017 Nov 3.
    *INSERM U1053, Team 3 Oncogenesis of Cutaneous Lymphomas §INSERM U1053, Team 1 Liver Cancer and Tumor Invasion, University of Bordeaux †Pathology Department ‡Dermatology Department ∥Tumor Biology and Tumor Bank Department, CHU Bordeaux, Bordeaux, France.
    As checkpoint molecules' inhibition may represent a therapeutic option in relapsing cases, we assessed programmed death ligands' (PD-L1/PD-L2) expression in a series of 29 primary cutaneous diffuse large B-cell lymphoma, leg-type (PCDLBCL-LT) cases. Double immunostaining for either PD-L1 or PD-L2 was associated either with PAX5 staining to evaluate tumor cells or with CD68 or CD163 staining for macrophages. The microenvironment of PCDLBCL-LT was characterized by immunostainings for CD3 (tumor-infiltrating lymphocytes), FOXP3 (regulatory T cells), programmed cell death-1, and CD33 (myeloid-derived suppressor cells). Read More

    Hodgkin's lymphoma arising in a case of mycosis fungoides: An unusual association.
    Indian J Dermatol Venereol Leprol 2017 Nov 3. Epub 2017 Nov 3.
    Department of Pathology, Vardhman Mahavir Medical College, Safdarjung Hospital, New Delhi, India.
    Mycosis fungoides is a cutaneous T-cell lymphoma with a high risk for developing secondary malignancies, especially B-cell lymphoproliferative disorders. About 40 cases of Hodgkin's lymphoma associated with mycosis fungoides have been reported in literature till date. We report a case of a 35-year-old gentleman who presented with intensely itchy reddish lesions all over the body. Read More

    Views of dermatopathologists about clonality assays in the diagnosis of cutaneous T cell and B cell lymphoproliferative disorders.
    J Cutan Pathol 2017 Oct 30. Epub 2017 Oct 30.
    Department of Dermatology, University of Iowa, Iowa City, Iowa.
    Background: Appropriate use criteria have been developed for many tests using expert judgment, evidence-based practice and clinical experience. In this context, the opinions of practitioners about clonality assays in various clinical scenarios where cutaneous lymphoma is suspected are reported.

    Methods: An Appropriate Use Criteria Task Force sponsored by the American Society of Dermatopathology (ASDP) synthesized clinical scenarios for cutaneous lymphoproliferative disorders (LPDs). Read More

    Pachyderma in Primary Cutaneous NK and T-Cell Lymphoma and Leukemia Cutis.
    Case Rep Dermatol 2017 Sep-Dec;9(3):151-157. Epub 2017 Sep 11.
    Department of Dermatology, Liège University Hospital, Liège, Belgium.
    Background: Pachyderma is defined as severely thickened skin with deep folds and is occasionally observed with primary cutaneous NK and T-cell lymphoma (pCNKTCL), primary cutaneous B-cell lymphoma (pCBCL), and leukemia cutis (LC).

    Aim: To describe the clinical, histological, and therapeutic particularities of a series of pCNKTCL, pCBCL, and LC patients with pachyderma.

    Results: In a series of pCNKTCL (n = 70), pCBCL (n = 12), and LC (n = 2) patients followed up during 9 years, 6 cases of pachyderma were observed. Read More

    Bilateral upper and lower eyelid margin swelling and madarosis due to lymphoma.
    Surv Ophthalmol 2017 Oct 3. Epub 2017 Oct 3.
    Department of Ophthalmology of the Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA; Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA; Department of Ophthalmology, The Ophthalmic Plastic and Reconstructive Surgery Service, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA.
    Over a 2-year period, swellings of all 4 eyelid margins developed in a 32-year-old woman and was accompanied by complete loss of eyelashes. An inflammatory dermatologic condition was considered the most likely cause. A full-thickness right lower eyelid biopsy revealed a multinodular lymphoid tumor at the eyelid margin which immunophenotypically and genetically was diagnosed as an extranodal marginal zone lymphoma. Read More

    Frequent immunoglobulin G4 expression in a common variant of primary cutaneous marginal zone B-cell lymphoma.
    Australas J Dermatol 2017 Oct 4. Epub 2017 Oct 4.
    Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China.
    Immunoglobulin (Ig)G4 expression was recently observed in a proportion of primary cutaneous marginal zone B-cell lymphoma (PCMZL) with plasmacytic differentiation. IgG4-related disease is characterised by polyclonal lymphoplasmacytic infiltration with IgG4 expression, storiform fibrosis and obliterative phlebitis in histopathology. Here we report three cases of common variants of PCMZL with predominant and varied IgG4 expression, suggesting there is an underlying clonal progression between these two entities. Read More

    Systemic and primary cutaneous anaplastic large cell lymphoma: Clinical features, morphological spectrum, and immunohistochemical profile.
    South Asian J Cancer 2017 Jul-Sep;6(3):129-131
    Department of Pathology, Louisiana State University Health Sciences Center, Shreveport, LA 71103, USA.
    Background: T-cell lymphomas with anaplastic morphology typically comprise of anaplastic lymphoma kinase positive, anaplastic large cell lymphoma (ALK+ ALCL), ALK-negative ALCL (ALK- ALCL), and primary cutaneous ALCL (PC-ALCL). However, other entities such as diffuse large B-cell lymphoma, peripheral T-cell lymphoma, Hodgkin lymphoma, and undifferentiated carcinoma can also show similar anaplastic features.

    Aims: To study the clinical features and histological spectrum of ALCL and emphasize the role of immunohistochemistry (IHC) in their diagnosis and categorization. Read More

    Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
    Blood 2017 Nov 2;130(19):2073-2083. Epub 2017 Oct 2.
    Department of Dermatology and.
    The presence and degree of peripheral blood involvement in patients with cutaneous T-cell lymphoma (CTCL) portend a worse clinical outcome. Available systemic therapies for CTCL may variably decrease tumor burden and improve quality of life, but offer limited effects on survival; thus, novel approaches to the treatment of advanced stages of this non-Hodgkin lymphoma are clearly warranted. Mutational analyses of CTCL patient peripheral blood malignant cell samples suggested the antiapoptotic mediator B-cell lymphoma 2 (BCL2) as a potential therapeutic target. Read More


    Cutaneous Richter Syndrome Mimicking Primary Cutaneous CD4-Positive Small/Medium T-cell Lymphoma: Case Report and Review of the Literature.
    Am J Dermatopathol 2017 Sep 12. Epub 2017 Sep 12.
    Serviço de Anatomia Patológica, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal.
    Richter syndrome represents the transformation of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma into an aggressive large B-cell lymphoma. Skin involvement is exceptionally rare, with <20 cases reported and its presence as the first presentation of CLL/small lymphocytic lymphoma, as an isolated skin lesion has never been described. Primary cutaneous CD4-positive small/medium T-cell lymphoma (CD4 PCSM-TCL) characteristically presents with a dense dermal infiltrate consisting primarily of small-/medium-sized pleomorphic T-cells and less than 30% large pleomorphic cells. Read More

    From a Better Understanding of the Mechanisms of Action of Histone Deacetylases Inhibitors to the Progress of the Treatment of Malignant Lymphomas and Plasma Cell Myeloma.
    Recent Pat Anticancer Drug Discov 2017 Sep 19. Epub 2017 Sep 19.
    "Lucian Blaga" University of Sibiu, Faculty of Medicine, Emergency County Clinical Hospital Sibiu, Sibiu. Romania.
    Background: Notable progress has been made in chemo- and immunotherapy of B-cell lymphomas, but less in the treatment of T-cell lymphomas.

    Objective: Histone deacetylases inhibitors are a potentially useful therapeutic mean, as an epigenetic dysregulation is present in lymphomas, and especially in T-cell types. We aimed to study the progress made in this area. Read More

    Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice.
    Oncoimmunology 2017 20;6(9):e1341031. Epub 2017 Jun 20.
    Department of Pediatrics, New York Medical College, Valhalla, NY.
    Facilitating the development of alternative targeted therapeutic strategies is urgently required to improve outcome or circumvent chemotherapy resistance in children, adolescents, and adults with recurrent/refractory de novo mature B-cell (CD20) non-Hodgkin lymphoma, including Burkitt lymphoma (BL). Romidepsin, a histone deacetylase inhibitor (HDACi), has been used to treat cutaneous T-cell lymphoma. We have demonstrated the significant anti-tumor effect of anti-CD20 chimeric antigen receptor (CAR) modified expanded peripheral blood natural killer (exPBNK) against rituximab-sensitive and -resistant BL. Read More

    Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, With Spontaneous Regression After Biopsy.
    Am J Dermatopathol 2017 Oct;39(10):785-787
    *Department of Dermatology, Complejo Hospitalario Universitario Insular Materno-Infantil, Universidad de Las Palmas de Gran Canaria, Canary Islands, Spain; and †Department of Pathology, Complejo Hospitalario Universitario Insular Materno-Infantil. Canary Islands, Spain.
    Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) represents approximately 20% of cutaneous B lymphomas with an intermediate prognosis. Spontaneous regression is uncommon; there are only 2 published cases. An 83-year-old woman presented 2 orange erythematous nodules on the back of her right leg with an elastic consistency, infiltrated, painful to the touch, and of an 8-month evolution. Read More

    Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies.
    Clin Lymphoma Myeloma Leuk 2017 Jul 14. Epub 2017 Jul 14.
    Department of Dermatology, Stanford University School of Medicine, Stanford, CA. Electronic address:
    The identification of oncogenic drivers of liquid tumors has led to the rapid development of targeted agents with distinct cutaneous adverse event (AE) profiles. The diagnosis and management of these skin toxicities has motivated a novel partnership between dermatologists and oncologists in developing supportive oncodermatology clinics. In this article we review the current state of knowledge of clinical presentation, mechanisms, and management of the most common and significant cutaneous AEs observed during treatment with targeted therapies for hematologic and lymphoid malignancies. Read More

    Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.
    Blood Cancer J 2017 Sep 8;7(9):e603. Epub 2017 Sep 8.
    Department of Haematology, Peter McCallum Cancer Centre, Melbourne, Victoria, Australia.
    CD30 is a member of the tumor necrosis factor receptor superfamily. It is characteristically expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma and Hodgkin lymphoma, among others. The variable expression of CD30 on both normal and malignant lymphoid cells has focused research efforts on understanding the pathogenesis of CD30 upregulation, its contribution to lymphomagenesis through anti-apoptotic mechanisms, and its effect on cell survival. Read More

    Dermoscopy and the diagnosis of primary cutaneous B-cell lymphoma.
    J Eur Acad Dermatol Venereol 2017 Aug 28. Epub 2017 Aug 28.
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, New York, NY, USA.
    Background: Primary cutaneous B-cell lymphomas (PCBCLs) are frequently misdiagnosed, and a biopsy is needed to attain the correct diagnosis.

    Objective: To characterize the dermoscopic features of PCBCL.

    Methods: In this retrospective observational study, we analysed the pathology reports of 172 newly diagnosed PCBCL for the initial clinical differential diagnosis. Read More

    Novel Mutations Involving NF-κB and B-Cell Signaling Pathways in Primary Cutaneous Large B-Cell Lymphoma, Leg-Type and Comparison with Sézary Syndrome.
    J Invest Dermatol 2017 Sep;137(9):1831-1833
    Department of Dermatology, Anderson Cancer Center, Houston, Texas, USA.
    Multiple genomic mutations, especially those involving the NF-κB pathway, have been characterized in primary cutaneous large B-cell lymphoma, leg type. However, its genomic profiling remains limited given its rarity. In a recent study, Mareschal et al. Read More

    Molecular analysis of immunoglobulin variable genes supports a germinal center experienced normal counterpart in primary cutaneous diffuse large B-cell lymphoma, leg-type.
    J Dermatol Sci 2017 Nov 26;88(2):238-246. Epub 2017 Jul 26.
    UMR CNRS 7276, Univ. Limoges,2 avenue Martin Luther King, 87042 Limoges, France.
    Background: Immunophenotype of primary cutaneous diffuse large B-cell lymphoma, leg-type (PCLBCL-LT) suggests a germinal center-experienced B lymphocyte (BCL2+ MUM1+ BCL6+/-).

    Objectives: As maturation history of B-cell is "imprinted" during B-cell development on the immunoglobulin gene sequence, we studied the structure and sequence of the variable part of the genes (IGHV, IGLV, IGKV), immunoglobulin surface expression and features of class switching in order to determine the PCLBCL-LT cell of origin.

    Methods: Clonality analysis with BIOMED2 protocol and VH leader primers was done on DNA extracted from frozen skin biopsies on retrospective samples from 14 patients. Read More

    Regression of diffuse B-cell lymphoma of the leg with intralesional gentian violet.
    Exp Dermatol 2017 Aug 20. Epub 2017 Aug 20.
    Department of Dermatology, Atlanta Veterans Administration Medical Center, Emory University School of Medicine, Atlanta, GA, USA.
    In this case report, a patient of primary cutaneous diffuse B-cell lymphoma, leg type was treated with intralesional gentian violet as she was judged to be too medically fragile for conventional chemotherapy due to advanced age and multiple serious comorbidities. Gentian violet (crystal violet/hexamethyl pararosaniline) is a triphenylmethane dye. It has been shown to have an inhibitory effect on NADPH oxidase, an enzyme family which is found in abundance in reactive oxygen-driven tumors such as melanoma and lymphoma. Read More

    Primary Cutaneous B-cell Lymphomas.
    Clin Lab Med 2017 Sep;37(3):547-574
    Department of Pathology, UCSF Dermatopathology Section, University of California, San Francisco, 1701 Divisidero Street, Room 280, San Francisco, CA 94115, USA; Department of Dermatology, UCSF Dermatopathology Section, University of California, San Francisco, 1701 Divisidero Street, Room 280, San Francisco, CA 94115, USA. Electronic address:
    B-cell lymphomas represent approximately 20% to 25% of primary cutaneous lymphomas. Within this group, most cases (>99%) are encompassed by 3 diagnostic entities: primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma, and primary cutaneous diffuse large B-cell lymphoma, leg type. In this article, the authors present clinical, histopathologic, immunophenotypic, and molecular features of each of these entities and briefly discuss the rarer intravascular large B-cell lymphoma. Read More

    An unusual presentation of chronic lymphocytic leukemia.
    Avicenna J Med 2017 Jul-Sep;7(3):133-136
    Department of Hematology Oncology, University of Arkansas for Medical Sciences, Winthrop Rockefeller Cancer Institute, Little Rock, Arkansas, USA.
    Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a B-cell lymphocytic neoplasm with indolent clinical course. If identified early, observation is opted. Many variables lead to the initiation of treatment. Read More

    Chronic lymphocytic leukemia/small lymphocytic lymphoma with t (2;18) (p12;q21) accompanied by a cutaneous nodule with histological features of diffuse large B-cell lymphoma.
    Rinsho Ketsueki 2017 ;58(7):749-754
    Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine.
    A 73-year-old woman presented a 3-year history of indolent enlargement of cutaneous tumor nodules. Peripheral blood flow cytometry revealed thrombocytopenia (platelets; 85,000/µl) and the presence of an abnormal, small B lymphocyte population (CD5(+), CD10(-), CD20(+), CD22(+), CD23(dim), FMC7(+), SmIgλ(+), and SmIgκ(-); 4,000/µl). Skin biopsy indicated infiltration of CD5(+), CD10(-), CD20(+), BCL2(+), BCL6(+), and cyclin D1(-) atypical large B-cells, suggesting diffuse large B-cell lymphoma. Read More

    Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
    Br J Haematol 2017 Nov 2;179(3):439-448. Epub 2017 Aug 2.
    Department of Haematology, University Hospital of Reims and UFR Médecine, Reims, France.
    Histological transformation (HT) to diffuse large B-cell lymphoma (DLBCL) is a rare and poorly reported complication of Waldenström macroglobulinaemia (WM). We performed a retrospective study of 77 WM patients with biopsy-proven transformation to DLBCL. The median time from WM diagnosis to HT was 4·6 years and 16 patients (21%) had never been treated for WM. Read More

    Cutaneous intravascular natural killer/T cell lymphoma with peculiar immunophenotype.
    Histopathology 2017 Dec 10;71(6):994-1002. Epub 2017 Oct 10.
    Department of Pathology, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain.
    Intravascular lymphoma (IVL) is a rare entity. Most cases are a variant of extranodal diffuse large B cell lymphoma, and fewer than 10% of the published cases are of T cell origin. Only intravascular B cell lymphoma is recognized as a distinct entity in the most recent World Health Organization (WHO) classification of lymphoproliferative disorders. Read More

    Oral bexarotene for post-transplant cutaneous T-cell lymphoma.
    Dermatol Ther 2017 Sep 26;30(5). Epub 2017 Jul 26.
    Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Organ transplant recipients receiving immunosuppression have an increased risk of developing post-transplant lymphoproliferative diseases (PTLDs). Traditionally, PTLDs refer to Epstein-Barr virus (EBV)-induced B-cell lymphoma. However, post-transplant T-cell lymphoma may also occur and tends to have a poorer response to reduced immunosuppressive therapy. Read More

    Possible role of Helicobacter pylori in diseases of dermatological interest.
    J Biol Regul Homeost Agents 2017 APR-JUN;31(2 Suppl. 2):57-77
    Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
    Helicobacter pylori is a gram-negative, flagellate, microaerophilic bacterium identified for the first time about 30 years ago, as a pathogenic factor of gastritis and peptic ulcer. Soon after, it was linked to several gastrointestinal and extra-gastrointestinal diseases (hematological, cardiovascular, neurological, pulmonary and ocular diseases, obesity, diabetes mellitus, growth retardation and extragastric MALT lymphoma). Association and possible cause-effect correlation with H. Read More

    Silent presentation of multiple metastasis Burkitt lymphoma in a child: A case report and review of the literature.
    Medicine (Baltimore) 2017 Jul;96(28):e7518
    aPediatrics Department bOncology Department, University of Medicine and Pharmacy "Gr. T. Popa", Iasi, Romania.
    Rationale: The Burkitt lymphoma (BL) is a very aggressive B-cell non-Hodgkin's lymphoma. It accounts for 34% of lymphoma cases in children.

    Patient Concerns: We present the case of a 6-year-old boy diagnosed with BL, who presented multiple contrasting elements of the disease: silent symptomatology, without involvement of the bone marrow at first, but with multiorgan infiltration and a fast evolution, despite starting the treatment shortly after the symptoms appeared. Read More

    Reviewing the current evidence supporting early B-cells as the cellular origin of Merkel cell carcinoma.
    Crit Rev Oncol Hematol 2017 Aug 3;116:99-105. Epub 2017 Jun 3.
    Department of Pathology, GROW-School for Oncology & Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands. Electronic address:
    Merkel cell carcinoma (MCC) is a highly malignant skin cancer characterized by early metastases and poor survival. Although MCC is a rare malignancy, its incidence is rapidly increasing in the U.S. Read More

    Risk of cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of non-Hodgkin lymphoma.
    Int J Dermatol 2017 Nov 7;56(11):1125-1129. Epub 2017 Jul 7.
    Department of Dermatology, Mayo Clinic, Rochester, MN, USA.
    Background: Second hematologic cancers in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) are well documented and include Hodgkin lymphoma, therapy-related acute myeloid leukemia/myelodysplastic syndromes, and transformation to diffuse large B-cell lymphoma. Although cutaneous T-cell lymphoma (CTCL) has been reported in patients with CLL, the incidence and comparison to expected rates are unknown. We evaluated the incidence of CTCL among patients with CLL or other non-Hodgkin lymphoma (NHL) subtypes using data from the Surveillance, Epidemiology, and End Results (SEER) Program. Read More

    A novel BLK-induced tumor model.
    Tumour Biol 2017 Jul;39(7):1010428317714196
    1 Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
    B-lymphoid tyrosine kinase (BLK) is a non-receptor tyrosine kinase belonging to the SRC family kinases. BLK is known to be functionally involved in B-cell receptor signaling and B-cell development. New evidence suggests that B-lymphoid tyrosine kinase is ectopically expressed and is a putative oncogene in cutaneous T-cell lymphoma and other T-cell malignancies. Read More

    [Mycosis fungoides in a heart transplant recipient].
    Ann Dermatol Venereol 2017 Oct 23;144(10):624-628. Epub 2017 Jun 23.
    Service de dermatologie, groupe hospitalier du Havre, hôpital J.-Monod, BP 24, 76083 Le Havre, France.
    Background: Skin cancer occurs frequently in organ transplant patients as a result of induced immunosuppression. Most cases involve carcinomas or B-cell lymphomas induced by the Epstein Barr virus (EBV). Cutaneous T-cell lymphomas remain rare. Read More

    Primary cutaneous large B-cell lymphoma of scalp: Case report of a rare variant.
    Indian J Pathol Microbiol 2017 Apr-Jun;60(2):268-271
    Department of Dermatology, R. N. Cooper Hospital, Mumbai, Maharashtra, India.
    Primary cutaneous large B-cell lymphoma (Bcl) is defined as a lymphoma composed of large cells constituting more than 80% of the infiltrate and absence of extracutaneous involvement after staging investigations. In the new World Health Organization/European Organization for Research and Treatment of Cancer classification, cutaneous Bcls with large cells are of three types - primary cutaneous large Bcl leg type (PCLBCLLT), primary cutaneous follicle center lymphoma diffuse type (PCFCLDT), and primary cutaneous large Bcls other (PCLBCLO). These three different types are distinct in terms of their clinicopathological features and survival. Read More

    Diagnostic value of STMN1, LMO2, HGAL, AID expression and 1p36 chromosomal abnormalities in primary cutaneous B cell lymphomas.
    Histopathology 2017 Oct 19;71(4):648-660. Epub 2017 Jul 19.
    Département de Biopathologie, CHU Montpellier, Hôpital Gui De Chauliac, Montpellier, France.
    Aims: Distinction between primary cutaneous follicular lymphoma (PCFL) and primary cutaneous marginal zone lymphoma (PCMZL) is challenging, as clear-cut immunophenotypical and cytogenetic criteria to segregate both entities are lacking.

    Methods And Results: To characterize PCFL and PCMZL more clearly and to define criteria helpful for the differential diagnosis, we compared expression of immunohistochemical markers [LIM-only transcription factor 2 (LMO2), human germinal centre-associated lymphoma (HGAL), stathmin 1 (STMN1), activation-induced cytidine deaminase (AID), myeloid cell nuclear differentiation antigen (MNDA)] and the presence of cytogenetic abnormalities described previously in nodal follicular lymphoma [B cell lymphoma 2 (BCL2) and BCL6 breaks, 1p36 chromosomal region deletion (del 1p36)] in a series of 48 cutaneous follicular and marginal zone lymphomas [cutaneous follicular lymphoma (CFL) and cutaneous marginal zone lymphoma (CMZL)]. Immunostaining for STMN1, LMO2, HGAL and AID allowed the distinction between CFL and CMZL, and STMN1 was the most sensitive marker (100% CFL, 0% CMZL). Read More

    Primary cutaneous B-cell lymphoma and chronic leg ulcers in a patient with type 2 diabetes.
    Endocrinol Diabetes Metab Case Rep 2017 24;2017. Epub 2017 May 24.
    Division of EndocrinologyDiabetes and Metabolism, Department of Medicine.
    The incidences of type 2 diabetes mellitus and many cancers are rapidly increasing worldwide. Diabetes is a strong risk factor for some cancers (including lymphomas) and is also associated with adverse cancer outcomes. After gastrointestinal tract, the skin is the second most frequent extranodal site involved by non-Hodgkin lymphomas and the cutaneous B-cell lymphomas (CBCLs) range from 25% to 30% of all primary cutaneous lymphomas. Read More

    The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers.
    Front Oncol 2017 12;7:93. Epub 2017 May 12.
    Department of Tumor Virology, German Cancer Research Center, Heidelberg, Germany.
    Non-Hodgkin lymphoma (NHL) and leukemia are among the most common cancers worldwide. While the treatment of NHL/leukemia of B-cell origin has much progressed with the introduction of targeted therapies, few treatment standards have been established for T-NHL/leukemia. As presentation in both B- and T-NHL/leukemia patients is often aggressive and as prognosis for relapsed disease is especially dismal, this cancer entity poses major challenges and requires innovative therapeutic approaches. Read More

    Primary Cutaneous B-Cell Lymphoblastic Lymphoma Arising from a Long-Standing Lesion in a Child and Review of the Literature.
    Pediatr Dermatol 2017 Jul 26;34(4):e182-e186. Epub 2017 May 26.
    Dermatology Program, Boston Children's Hospital, Boston, Massachusetts.
    Precursor B-cell lymphoblastic lymphoma (B-LBL) is a rare entity and primary cutaneous B-LBL is an even more uncommon diagnosis that typically affects children. A 4-year-old boy presented with a persistent rash on his left cheek for almost 2 years and was found to have primary cutaneous B-LBL. We report this case to emphasize that B-LBL should be in the differential diagnosis for an otherwise unimpressive persistent lesion in the head and neck region and review all reported pediatric cases of primary cutaneous B-LBL without extracutaneous involvement. Read More

    1 OF 50